https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3ADiabetes_medication%2F27%2FenTranslations:Diabetes medication/27/en - Revision history2026-07-17T20:50:57ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:Diabetes_medication/27/en&diff=110571&oldid=prevFuzzyBot: Importing a new version from external source2024-02-04T03:09:12Z<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>Current clinical practice guidelines from the [[American Association of Clinical Endocrinologists|AACE]] rate sulfonylureas (as well as glinides) below all other classes of antidiabetic drugs in terms of suggested use as first, second, or third line agents - this includes [[bromocriptine]], the bile acid sequestrant [[colesevelam]], [[Alpha-glucosidase inhibitor|α-glucosidase inhibitors]], [[Thiazolidinedione|TZDs]] (glitazones), and [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitors]] (gliptins). The low cost of most sulfonylureas, however, especially when considering their significant efficacy in blood glucose reduction, tends to keep them as a more feasible option in many patients - neither SGLT2 inhibitors nor GLP-1 agonists, the classes most favored by the AACE guidelines after metformin, are currently available as generics.</div>FuzzyBot